Rezultaty 1 - 2 Rezultaty od 2, Czas wyszukiwania: 0,04s Redukuj rezultaty
  1. 1
    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC od Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I

    Wydane 2021
    Conference item
  2. 2
    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC

    Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PSA-1 and SELECT-PsA-2 trials assessed according to modified PsARC od Coates, LC, Garrood, T, Gullick, N, Helliwell, P, Kent, T, Marks, J, Tillett, W, Kaur-Papadakis, D, Tahir, H, van Haaren, S, McInnes, I

    Wydane 2022
    Journal article

Narzędzie wyszukiwania: